Drug Patents owned by Albireo
1. Drug name - BYLVAY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7132416 | ALBIREO | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(30 days ago) | |
| US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
| IN200400539P1 | ALBIREO | Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia |
Sep, 2022
(30 days ago) | |
| IN248635B | ALBIREO | Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia |
Sep, 2022
(30 days ago) | |
| EP1427423A1 | ALBIREO | Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia |
Sep, 2022
(30 days ago) | |
| EP1427423B1 | ALBIREO | Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia |
Sep, 2022
(30 days ago) | |
| EP1427423B9 | ALBIREO | Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia |
Sep, 2022
(30 days ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10981952 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(9 years from now) | |
| US9694018 | ALBIREO | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(9 years from now) | |
| US10487111 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(9 years from now) | |
| US10093697 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(9 years from now) | |
| US10011633 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(9 years from now) | |
Drugs and Companies using ODEVIXIBAT ingredient
Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.2MG | CAPSULE, PELLETS;ORAL | Prescription |
| 0.6MG | CAPSULE, PELLETS;ORAL | Prescription |
| 0.4MG | CAPSULE;ORAL | Prescription |
| 1.2MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.